MARKET

CTXRW

CTXRW

CITIUS PHARM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2201
0.0000
0.00%
Closed 16:00 11/27 EST
OPEN
0.2201
PREV CLOSE
0.2400
HIGH
--
LOW
--
VOLUME
0
TURNOVER
--
52 WEEK HIGH
0.7500
52 WEEK LOW
0.1200
MARKET CAP
--
P/E (TTM)
-0.3984
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
No Data
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTXRW. Analyze the recent business situations of CITIUS PHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.20%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Executive Director/Secretary
Leonard Mazur
President/Chief Executive Officer/Director
Myron Holubiak
Chief Financial Officer
Jaime Bartushak
Independent Director
Suren Dutia
Independent Director
Eugene Holuka
Independent Director
William Kane
Independent Director
Howard Safir
Independent Director
Carol Webb
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CTXRW
Citius Pharmaceuticals Inc is a specialty pharmaceutical company. The Company is focused on developing and commercializing care products with a focus on anti-infective products in adjunct cancer care and prescription products. It has three product candidates: Mino-Lok, CITI-002 (halobetasol-lidocaine formulation) and CITI-101 (Mino-Wrap). Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Mino-Lok product is designed to salvage the central venous catheters CVC, obviating the need to remove and replace the catheter. Mino-Wrap is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. CITI-002 is being developed for symptomatic relief of hemorrhoids. CITI-002 combines the steroid, halobetasol, with lidocaine.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Citius Pharmaceuticals Inc stock information, including NASDAQ:CTXRW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTXRW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTXRW stock methods without spending real money on the virtual paper trading platform.